The addition of ADXS-503 to the treatment of patients with metastatic non–small cell lung cancer who were progressing on pembrolizumab (Keytruda) resulted in encouraging responses and durable disease control, according to findings from the phase 1/2 trial.
Jared Weiss, MD, sheds light on the exploration of adagrasib as a monotherapy and in combination with cetuximab in patients with KRAS G12C–mutated metastatic colorectal cancer, key findings from the KRYSTAL-1 study, and next steps for research.
Low Country Cancer Care is pleased to announce the opening of their new cancer center in Statesboro, Ga., located at 1601 Fair Road, Suite 900. This new clinic is the fifth LCCC location, making it easier for patients to have access to the highest quality cancer care close to where they live.
Christopher S. Lathan, MD, MS, MPH, discusses the lack of dissemination and implementation of evidence-based health care delivery innovations focused on addressing disparities in care.
Thomas Kipps, MD, PhD, discussed navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS.
Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.
The FDA has granted a regenerative medicine advanced therapy designation and a fast track designation to C-CAR039 for use as a potential therapeutic option in patients with relapsed or refractory diffuse large B-cell lymphoma.
James K. McCloskey, MD, discusses the efficacy of oral decitabine plus cedazuridine, the combination’s potential role in lower-risk myelodysplastic syndromes, and what this could mean for the patient population.
Sara Hurvitz, MD, discusses the findings from the subgroup analysis of the DESTINY-Breast03 trial, and future research directions for trastuzumab deruxtecan.
Liquid biopsies are critical in understanding oncogenic drivers and resistance mechanisms in patients with non–small cell lung cancer.
Chih-Yi (Andy) Liao, MD, discusses the focus of each presentation at the webinar, which centered on optimizing therapy in advanced pancreatic cancer, the contemporary use of surgery and systemic therapy in NETs, multidisciplinary approaches to hepatocellular carcinoma, and the evolving role of liver transplant and systemic therapy.
Cancer Treatment Centers of America's comprehensive cancer centers in Chicago and Atlanta earned the 2021 Guardian of Excellence Award from Press Ganey as top performers in patient experience.
High expression of activated leukocyte cell adhesion molecule, also known as CD166, occurs in approximately 50% of patients with triple-negative breast cancer and up to 80% of patients with estrogen receptor– positive, HER2-negative breast cancer.
The FDA has agreed upon key elements, including design features and operational details, for the phase 3 ZILO-301 trial, which will evaluate zilovertamab in combination with ibrutinib in patients with relapsed or refractory mantle cell lymphoma.
Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.
Srdan Verstovsek, MD, PhD, discusses the key objective of the phase 3 IMpactMF trial examining imetelstat in patients with myelofibrosis.
John M. Burke, MD, highlights the benefits derived with polatuzumab vedotin plus R-CHP and projects the next steps for the regimen.
The FDA has granted a breakthrough device designation to BNT200, a prescription-only digital therapeutic to leverage in the treatment of anxiety and depressive symptoms created by psychological stressors experienced by adults with acute myeloid leukemia who are hospitalized and undergoing high-intensity induction chemotherapy.
The combination of pembrolizumab and enzalutamide continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who were previously treated with abiraterone acetate, according to data from cohort C of the phase 1b/2 KEYNOTE-365 trial.
The diffusing alpha-emitter radiation therapy, Alpha DaRT, was found to elicit complete responses per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who are enrolled to an ongoing single-institution pilot feasibility trial.
Following an extensive, nationwide search, Goldie Taylor has been named Senior Vice President, Chief Communication and Marketing Officer at Dana-Farber Cancer Institute.
The Data Safety Monitoring Board has determined that it is safe and appropriate to continue recruitment to the expansion arm of the phase 1/2 GLORIA trial, which is examining a novel combination comprised of NOX-A12, radiotherapy, and bevacizumab in glioblastoma and incomplete tumor resection.
When treating cancers that are considered generally incurable, such as multiple myeloma, one of the paradigms in oncology is to deliver the most effective therapies upfront to maximize the chances of prolonging remission.
Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma, and the humanized anti-disialoganglioside monoclonal antibody hu14.18K322A could provide a breakthrough for children with high-risk disease.
The novel antimetabolite aspacytarabine was found to produce a complete remission rate of 37% in adult patients with newly diagnosed acute myeloid leukemia who are unfit for intensive therapy.
As the armamentarium of advanced non–small cell lung cancer () continues to grow with the addition of novel targeted therapies for rare patient subtypes, the field is simultaneously shifting to evaluate targeted therapy and immunotherapy in earlier lines of treatment, including the neoadjuvant and adjuvant spaces.
The European Commission has granted conditional marketing authorization to sotorasib for the treatment of adult patients with KRAS G12C mutant advanced non–small cell lung cancer.
The FDA has granted a fast track designation to enobosarm as a potential therapeutic option for patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative, metastatic breast cancer who progressed on a nonsteroidal aromatase inhibitor, fulvestrant, and a CDK4/6 inhibitor, and who have AR staining of 40% or more in cancer tissue.
New research led by Yale Cancer Center reveals young women with breast cancer and a family history of the disease, but no high penetrance germline mutations, have an increased number of rare germline variants in cancer relevant genes
Adjuvant treatment with pembrolizumab led to a statistically significant and clinically meaningful improvement in disease-free survival vs placebo in patients with stage IB to IIIA non–small cell lung cancer following resection, regardless of PD-L1 expression, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.
